Treatment
Sintilimab clinical trials
We’re tracking 175 recruiting studies that include Sintilimab, each written for real people, not researchers, below.
Recruiting studies
- NCT06329973RecruitingPhase 1/Phase 2
Fruquintinib, sintilimab, and chemo for stomach cancer
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Zhengzhou, HenanAges 18–75 - NCT07457281RecruitingPhase 1
A new drug combo for head and neck cancer before surgery
This trial tests two drugs, GV20-0251 and Sintilimab, given before surgery for head and neck cancer. The goal is to see if this combination can shrink tumors and make surgery more effective.
ChengduAges 18–70 - NCT06808412RecruitingPhase 2
Sintilimab plus bevacizumab for untreated rectal cancer
This trial tests two drugs—sintilimab (an immunotherapy) and bevacizumab (a targeted therapy)—for people with rectal cancer that hasn't been treated yet. It aims to see if this combination can shrink the tumor before surgery.
Xi'an, ShaanxiAges 18–75 - NCT07263386RecruitingPhase 2
Immunotherapy plus chemo for PD-L1-positive stomach cancer
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
Nanjing, JiangsuAges 18–75 - NCT06761846RecruitingPhase 2
Immunotherapy and chemo after stomach cancer surgery
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from coming back. You may qualify if you had D2 surgery and your tumor tested positive for PD-L1.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07518602RecruitingPhase 2
Chidamide, Sintilimab, and Bevacizumab for Advanced Neuroendocrine Cancer
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Guangzhou, GuangdongAges 18–75 - NCT05839275RecruitingPhase 1/Phase 2
Radiation plus two medicines for high-risk soft tissue sarcoma
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06714708RecruitingPhase 2
Low-dose radiation with immunotherapy and chemo before surgery for lung cancer
This trial tests a combination of low-dose radiation, an immunotherapy drug called sintilimab, and standard chemotherapy before surgery for stage II–III non-small cell lung cancer (NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes for patients who are candidates for surgery.
Hefei, AnhuiAges 18 years+ - NCT06583083RecruitingPhase 2
Sintilimab plus chemo vs chemo alone for advanced ENKTL lymphoma
This trial tests whether adding the immunotherapy drug sintilimab to a standard chemotherapy regimen (P-GEMOX) works better than chemotherapy alone for people with advanced ENKTL lymphoma. The goal is to see if the combination improves outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT07400302RecruitingPhase 2
Sintilimab plus chemo for resected mucosal melanoma
This trial tests if adding sintilimab (an immunotherapy) to chemotherapy after surgery can lower the chance of mucosal melanoma coming back. It is for people whose melanoma has been fully removed and whose tumor tests positive for PD-L1.
Changchun, JilinAges 18 years+ - NCT06904014RecruitingPhase 2
Testing a new drug combo before surgery for liver cancer
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
Jinan, ShandongAges 18–70 - NCT07350850RecruitingPhase 2
Methotrexate plus immunotherapy combo for untreated PCNSL
This trial tests a new combination of drugs (methotrexate, rituximab, sintilimab, and pirtobrutinib) against standard therapy for people with newly diagnosed primary central nervous system lymphoma (PCNSL) that has not been treated before. It aims to see if the combo works better and has manageable side effects.
Xiamen, FujianAges 18 years+ - NCT06543069RecruitingPhase 2
Combination therapy for unresectable peritoneal mesothelioma
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
BeijingAges 18 years+ - NCT06931808Enrolling by invitationPhase 4
Fecal transplant with chemo, radiation, and immunotherapy for advanced colon cancer
This study tests a combination of fecal microbiota transplant, chemotherapy, radiation, and immunotherapy (sintilimab) for people with locally advanced rectal cancer. The goal is to see if this approach improves treatment outcomes.
Ningbo, ZhejiangAges 18–75 - NCT06685276RecruitingPhase 2
Combination therapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
BeijingAges 18–75 - NCT05429463RecruitingPhase 3
Surgery-ready lung cancer treatment with immunotherapy plus chemo
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
Hangzhou, ZhejiangAges 18–75 - NCT07521852RecruitingPhase 2
New drug combination with immunotherapy for liver cancer
This trial tests a new drug called CVM-1118 combined with an immunotherapy drug (sintilimab) and a procedure called TACE (a catheter-based treatment that delivers medicine directly to tumors) in people with hepatocellular carcinoma (liver cancer) that cannot be cured by surgery. The goal is to see if this combination is effective and safe.
Fuzhou, FujianAges 18 years+ - NCT04589754RecruitingPhase 2
Chemotherapy plus immunotherapy for advanced soft-tissue sarcoma
This Phase 2 trial tests a combination of chemotherapy drugs (Adriamycin and ifosfamide) together with an immunotherapy drug (sintilimab) for advanced soft-tissue sarcoma that can’t be removed by surgery or has stopped responding to standard treatment. It aims to shrink tumors and help control the cancer by boosting the immune system along with chemotherapy.
Guangzhou, GuangdongAges 14–70 - NCT04636008RecruitingPhase 1/Phase 2
Immunotherapy with radiation for MSI-H or dMMR rectal cancer
This trial tests the drug sintilimab combined with a specific radiation schedule to treat rectal cancer that is MSI-H or dMMR (tumor DNA repair/instability markers). It may help shrink the tumor and improve outcomes when standard options are limited or not yet started.
Chengdu, SichuanAges 18 years+ - NCT04973293Recruiting
Pre-surgery immunotherapy plus chemo and blood-vessel medicine for lung cancer
This study tests whether giving sintilimab (an immune therapy) combined with bevacizumab (a blood-vessel–targeting medicine) plus chemotherapy before surgery can improve outcomes for resectable lung cancer. It’s meant for people with specific lung cancer types and good health for surgery, and it avoids certain cancer types and immune-related risks.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05010681RecruitingPhase 2
Lenvatinib plus immunotherapy after prior liver cancer treatment
This Phase 2 trial tests lenvatinib combined with the immunotherapy drug sintilimab in people with advanced liver cancer who got worse after prior PD-1/PD-L1 treatment. It aims to slow cancer growth and improve outcomes after immune therapy hasn’t worked.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05165407RecruitingPhase 2
Study drugs for advanced high-grade neuroendocrine tumors
This trial tests whether adding three medicines—sintilimab, IBI310, and surufatinib—can control advanced, high-grade neuroendocrine tumors (that cannot be removed by surgery or have spread). It may help if your cancer has grown despite standard treatment, or if you cannot take standard treatment due to side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT05188859RecruitingPhase 2
Testing sintilimab, anlotinib, and chemo for pleural mesothelioma
This Phase 2 study tests whether adding three medicines—sintilimab, anlotinib, and standard platinum chemo—can control malignant pleural mesothelioma that cannot be removed by surgery. It may help shrink tumors and slow disease progression, but you must meet specific health and prior-treatment requirements.
Taiyuan, ShanxiAges 18 years+ - NCT05450029RecruitingPhase 2
Adding immunotherapy to chemo-radiation for rectal cancer
This Phase 2 trial studies whether adding sintilimab (an immunotherapy drug) to standard chemo-radiation before surgery can improve outcomes for people with locally advanced rectal cancer. It’s aimed at tumors with certain immune “signature” scores and specific cancer stage features.
Guangzhou, GuangdongAges 18–75
Common questions
- Are there clinical trials studying Sintilimab?
- Yes. Clin2 currently lists 175 recruiting studies that include Sintilimab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Sintilimab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Sintilimab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Sintilimab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.